315 2012 COPD 2005 2011 [1-2] 2010 [3-4] [5] 3.7 / 10 [6] 52 / 10 [5] 100 / 10 18 ~ 34 4.2 / 10 70 272 / 10 [7] CT 50 CT - COPD 15% ~ 30% COPD 50% [11] DOI: 10. 3877/ cma. j. issn. 1674-6880. 2012. 05. 005
316 1. 1 Williams-Campbell 2-3 Marfan's syndrome / 2. 1 6% ~ 48% common variable immunodeficiency CVID X- X-linked agammaglobulinemia XLA lga - IgA IgG acquired immune deficiency syndrome AIDS 40% primary ciliary dyskinesia PCD Kartagener Young's syndrome 2 60% ~ 80% CD4 +
317 IL-16 IL-8 IL-10 -α tumor necrosis factor-α TNF-α -1 1. 3 allergic hronchopulmonary aspergillosis ABPA 2. 3 1 2 3 3. -
318 1. 41%~ 69% 2. 3. 4. - 5. [A] 6% ~ 48% CVID XLA IgA 6. 7. ABPA [12] 8. 2.9% ~ 5.2% CT
319 59% 9. 10. α1- α1-1. > 90% 75% ~ 100% 72% ~ 83% FEV 1 CT 2. 1 1 X IgG IgA IgM CT CT IgE 1. 1 X X X
320 X X X 2 CT CT 0.62 ± 0.13 < 80% CT CT 4 CT CT CT ABPA CT CT CT 3 CT 2. 1 ESR C 2 IgG IgA IgM [A] 3 IgE ABPA 4 5 ABPA l h 3 6 anti-neutrophil
321 cytoplasmic antibody ANCA IgE IgG B 7 8 2 9 3. 1 CT 2 FEV 1 FVC 1 4 > 80% 33% ~ 76% FEV 1 40% FEV 1 FVC 24 h
322 1. CT CT COPD 2. 1 2 3 1. COPD 2 COPD COPD 2 X CT FEV 1 / FVC < 70%) 2. 3 3 40 FEV 1
323 CT 1 [B] CT 4 1 ~ 2 h 2 3 [A] 3 [13] 4 β2- [B] 5 min FEV 1 5 [A] 4 1 2 3 45 30 1 + 2 3 4 5 30 45 4 5 45 6 8 9 10 7 30 1 ~ 2 20 ~ 30 min [B]
324 60% ~ 80% [14-15] [15] [1 2 4 3 3 FEV < 30% 4 2 > 2 4 2 ] [2] 5 5 / / + β- / / 14 d 1. 200 ml 24 h 500 ml
325 45 2. 1 3 ~ 5 min 20 ~ 30 min 5 ~ 10 U 5% 20 ~ 40 ml 15 min 10 ~ 20 U 5% 500 ml 0.1 U kg -1 h -1 2 ~ 3 d 2 4 ~ 6 g + 100 ml 15 ~ 30 min 1 g / h 100 ~ 200 mg 5% 40 ml 2 / d 250 ~ 500 mg 2 ~ 3 / d l ~ 2 ku 5 ~ 10 min 24 h 3 150 mg 30 ml l ~ 2 / d 0.25% 0.1 ml 5 ~ 10 mg 20 ~ 40 ml 10 ~ 20 mg 500 ml 3. 1 90% 1 70% [16] 2 93% 1 51% 2 39% [17] 34.5% 2 3 1. DNA [A] 2. β2-3.
326 [B] 1. 1 2 3 10 10% ~ 19% < 5% 2. 1++ RCT 1+ RCT 1- RCT 2++ 2+ 2-3 4 A B C 1++ RCT 1+ 2++ 1++ 1+ 2+ 2++ D 3 4 2+ A B 500 mg / kg [18]
327 1. 2. 3. 4. 5. 6. 1 Woodhead M, Blasi F, Ewig S, et al. European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005, 26 (6): 1138-1180. 2 Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect. 2011, 17 Suppl 6: E1-E59. 3 Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-cf bronchiectasis. Thorax. 2010, 65 Suppl 1: i1-i58. 4.. 2011 34 11 812-815. 5 Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Am J Respir Crit Care Med, 2004, 169: A330. 6 Twiss J, Metcalfe R, Edwards E, et al. New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch Dis Child, 2005, 90 (7): 737-740. 7 Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin
328 Pulmon Med, 2005, 12: 205-209. 8 Crofton J. Bronchiectasis. In: Crofton J, Douglas A, eds. Respiratory diseases. 3 rd eds. Oxford: Blackwell Scientific, 1981: 417-430. 9 Patel IS, Vlahos I, Wilkinson TM, et al.. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2004, 70 (4): 400-407. 10 O'Brien C, Guest PJ, Hill SL, et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax, 2000, 55 (8): 635-642. 11 King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis, 2009, 4: 411-419. 12.. 2003 26 559-562. 14 Pang JA, Cheng A, Chan HS, et al. The bacteriology of bronchiectasis in Hong Kong investigated by protected catheter brush and bronchoalveolar lavage. Am Rev Respir Dis, 1989, 139 (1): 14-17. 15 Angrill J, Agustí C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax, 2002, 57: 15-19. 16 Anuradha C, Shyamkumar NK, Vinu M, et al. Outcomes of bronchial artery embolization for lifethreatening hemoptysis due to tuberculosis and post-tuberculosis sequelae. Diagn Interv Radiol, 2012, 18(1): 96-101. 17 Samara KD, Tsetis D, Antoniou KM, et al. Bronchial artery embolization for management of massive cryptogenic hemoptysis: a case series. J Med Case Rep, 2011, 5: 58. 18 Chang CC, Singleton RJ, Morris PS, et al. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev. 2009, 2: CD006316.. 2012 [ J/ CD]. 2012 5( 5) 315-328.